Teva Pharmaceutical Industries (“Teva”), the maker of the multiple sclerosis drug Copaxone, allegedly boosted the drug’s price tag from $17,000 to $73,000 per year—turning an already pricy medication into a completely inaccessible one for many. If you’re concerned that you’ve been paying too much for Copaxone, Keller Rohrback wants to hear from you.

Do you use Victoza or another incretin mimetic to help control your Type 2 diabetes? If so, you’ve likely been affected by the soaring price increases for this important drug. To learn more, please contact Keller Rohrback’s consumer protection team at consumer@kellerrohrback.com, (800) 776-6044, or by using the secure form on this page.